News

In 2010, the US Food and Drug Administration (FDA) had approved Zuplenz for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and

"The majority of women with ovarian cancer will become resistant to platinum therapy and a quarter of women will have platinum-resistant disease at the time of a first

This collaboration involves analysis and interpretation of next-generation sequencing data from more than 1,000 exomes and genomes to identify new genetic variants associated with the disease. "Collaboration is

The ‘478 patent application includes newly allowed claims directed to compositions including those comprising a modified RNA agent linked to a biantennary or triantennary ligand. Specifically, the allowed

The new patent (US Pat. No. 8,778,373) provides OPKO with additional intellectual property protection covering controlled release administration of a vitamin D compound. OPKO is on schedule to

Such clearance will permit Galmed to conduct clinical trials of its product candidate, aramchol, in the United States for the treatment of fatty liver disorders. Galmed is initially

Taiho has a long history of developing new therapeutic options to serve the needs of oncologists and cancer patients. Our development of TAS-102 is an example of our

The ubiquitin system alterations are related to many common diseases, including cancer, diabetes, inflammation and several central nervous system (CNS) disorders. Scientists from Boehringer and the Toronto academic

Presently, there are no antibiotics, systemic or topical, which are specifically approved by the US Food and Drug Administration (FDA) to treat patients with Mild DFI. FDA has